Clinical trial registry record

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 11, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02540954
Last registry update
June 11, 2021
Status
Completed
Phase
Phase 3
Sponsor
Bayer
Enrollment
336
Countries
Austria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
336
Population
ALL · 51 Years
Duration
2015-09-29 to 2020-06-04
Intervention
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Comparator
Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)
Outcomes measured
Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for…; Percentage of Participants Maintaining Vision in the Study Eye — At week 52; Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye — At week 52; Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye — From baseline to week 52; Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye — From baseline to week 52; Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye — At week 52; Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire…; Number of Participants With Treatment-emergent Adverse Events (TEAE) — Started after the first application of afliberce…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON